BridgeBio Pharma Invites You to an Engaging Investor Webinar
Palo Alto, California – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a biopharmaceutical company committed to innovative treatments for genetic diseases, is set to host an engaging investor webinar. This event will occur on a Wednesday morning, bringing together experts in the field to delve into the complexities of autosomal dominant hypocalcemia type 1 (ADH1).
Understanding ADH1: A Critical Overview
During the webinar, Dr. Rachel Gafni, a Senior Research Physician with extensive experience at the National Institute of Dental and Craniofacial Research, will lead discussions. Her insights will focus on ADH1's pathophysiology, the significant unmet medical needs, and the promising potential of encaleret as a treatment for this rare genetic disorder.
In-Depth Insights from Experts
In addition to Dr. Gafni's presentation, key executive members from the ADH1 program team will share vital updates on the encaleret clinical development program. They will provide details on the ongoing Phase 3 CALIBRATE study, with expectations for topline results to emerge during the upcoming fall.
Webinar Accessibility and Replay Options
This informative session will be accessible to all interested parties via the live webcast, available through the "Events & Presentations" page on the company's investor website. For those unable to attend, a replay option will be provided, maintaining viewer engagement for 30 days following the event.
About BridgeBio Pharma, Inc.
Founded in 2015, BridgeBio Pharma, Inc. is revolutionizing the approach to treating genetic disorders. The company focuses on discovering, creating, testing, and delivering transformative medicines aimed at genetic disease management. Their robust pipeline features a diverse spectrum of development programs, ensuring advancements from early scientific discovery to late-stage clinical trials.
Connect with BridgeBio
Investors and stakeholders are encouraged to learn more by visiting bridgebio.com and following the company on various social media platforms to stay updated on the latest news and developments. BridgeBio’s commitment to applying cutting-edge genetic medicine represents a new horizon in the treatment of genetic disorders.
Contact Information for Further Inquiries
For more details, the media can contact Bubba Murarka, who serves as the Executive Vice President. Reach out via email at contact@bridgebio.com or by phone at (650) 789-8220. For investor relations, Chinmay Shukla, Senior Vice President, is available via email at ir@bridgebio.com.
Frequently Asked Questions
What is the purpose of the BridgeBio investor webinar?
The webinar aims to provide insights into the ongoing efforts and developments in treating autosomal dominant hypocalcemia type 1 (ADH1) and to showcase the clinical progress of encaleret.
Who will speak during the webinar?
Dr. Rachel Gafni, along with members of the ADH1 program team, will provide in-depth insights into the disease and the company's developmental efforts.
How can I attend the live webcast?
Access the live webcast through the "Events & Presentations" section on the BridgeBio investor website.
Will there be a replay of the webinar?
Yes, a replay will be available on the BridgeBio website for 30 days after the event for those unable to attend live.
What is BridgeBio Pharma's commitment to genetic diseases?
BridgeBio is dedicated to discovering and delivering innovative treatments for genetic disorders through their diverse pipeline and experienced team.
